NeuroVive Pharmaceutical (OTCMKTS:NEVPF) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Valuation & Earnings

This table compares NeuroVive Pharmaceutical and Cellectar Biosciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NeuroVive Pharmaceutical N/A N/A -$7.87 million ($0.11) -1.26
Cellectar Biosciences N/A N/A -$13.24 million ($4.66) -0.49

NeuroVive Pharmaceutical is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

NeuroVive Pharmaceutical has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for NeuroVive Pharmaceutical and Cellectar Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroVive Pharmaceutical 0 0 0 0 N/A
Cellectar Biosciences 0 0 2 0 3.00

Cellectar Biosciences has a consensus price target of $4.00, suggesting a potential upside of 73.91%. Given Cellectar Biosciences’ higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than NeuroVive Pharmaceutical.

Profitability

This table compares NeuroVive Pharmaceutical and Cellectar Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NeuroVive Pharmaceutical N/A -61.92% -54.40%
Cellectar Biosciences N/A -169.87% -115.68%

Institutional and Insider Ownership

4.9% of Cellectar Biosciences shares are owned by institutional investors. 8.5% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NeuroVive Pharmaceutical Company Profile

NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in phase II clinical trial for the treatment of traumatic brain injuries; and KL1333 that is in phase I clinical trial for the treatment of genetic mitochondrial diseases. The company also develops NVP015/NV354 drug candidates for mitochondrial diseases; NVP025 drug candidate for mitochondrial myopathies; NV556 and NVP022 drug candidates for non-alcoholic steatohepatitis conditions; and NVP024, a hepatocellular carcinoma program. NeuroVive Pharmaceutical AB (publ) has collaboration agreements with Isomerase Therapeutics, Sihuan Pharmaceutical, and Sanofi Korea. The company also has a preclinical collaboration agreement with the Children's Hospital of Philadelphia for research in genetic mitochondrial disorders. NeuroVive Pharmaceutical AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Receive News & Ratings for NeuroVive Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroVive Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.